Keyuan Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 31.4707 million yuan, a decrease of 20.69%

Keyuan Pharma released its Q3 2025 report, with operating revenue for the first three quarters at 303 million yuan, a year-on-year decrease of 8.52%. The net profit attributable to the parent company was 31.4707 million yuan, a year-on-year decline of 20.69%; the net profit excluding non-recurring gains and losses was 22.6467 million yuan, a year-on-year decrease of 15.84%. The basic earnings per share were 0.2906 yuan